

CLINICAL AND SONOGRAPHIC EFFECTS OF LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE IN PATIENTS WITH ADENOMYOSIS WITH OR WITHOUT ASSOCIATED ENDOMETRIOSIS IN A TERTIARY REFERRAL HOSPITAL AT FOUR-YEAR FOLLOW-UP: RESULTS FROM A PROSPECTIVE STUDY



Valdés-Bango M., Martínez-Zamora Mª., Gracia M., Quintas L., Rius M., Ros C., Carmona F.

Department of Gynecology, Institut Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clínic, Barcelona, Spain

BACKGROUND AND OBJECTIVE

To investigate the clinical and sonographic effects of the 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) in patients with adenomyosis with or without associated endometriosis in a long-term follow-up.

MATERIAL AND METHODS

This prospective study included 28 patients with diagnosis of with adenomyosis with or without associated endometriosis who underwent LNG-IUD insertion between January 2016 and December 2017 in the Department of Gynecology of the Hospital Clinic of Barcelona. A numeric rating scale score from 1 to 10 for pain at baseline and 48 months after the LNG-IUD insertion were used to assess the efficacy of the treatment. A high-resolution specialized ultrasound was performed at every follow-up visit searching for criteria of adenomyosis and reporting the size of the deep endometriosis nodules and ovarian endometriomas.

RESULTS






Table 1. Baseline clinical characteristics among patients

Songraphic findings: A significant reduction in the sonographic expression of adenomyosis after treatment was identified with a complete response to treatment in 11 (39.3%) patients (p<0.004). The number of patients who met >3 criteria of adenomyosis decreased from 23 to 8 (p=0.004). There was a trend in a decrease in mean size of OE (39 to 23 mm) and DE nodules (34 to 25 mm) although it did not reach statistical significance.

CONCLUSIONS

The LNG-IUD appears to be an effective method in alleviating pain and heavy menstrual bleeding symptoms associated with adenomyosis and/or endometriosis in the long term. Sonographic improvement is also demonstrated at 48-month follow-up, especially regarding adenomyosis and OE compared with DE. Further research with a longer follow-up, larger sample size and comparison with other treatments are needed.